EMA starts safety-related review of obesity drug

The EMA has started a review of drugs containing substance amfepramone, which is typically used to dampen appetites as a treatment for obesity.

Photo: Rob Acket/EMA

Following a request from the Romanian medicines agency, the European Medicines Agency (EMA) has started reviewing the substance amfepramone, which is an ingredient in several drugs used for treating obesity.

The drug works by dampening the appetite in patients, for which reason it is only used as a temporary treatment in combination with other elements, such as changing the patient's diets and exercise habits.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs